Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Longholder99on Jan 22, 2023 6:08pm
251 Views
Post# 35238828

RE:RE:RE:RE:RE:somethings gotta give...

RE:RE:RE:RE:RE:somethings gotta give...CancerSlayer I agree too that timeliness have a way of being longer...way longer.  Only consideration giving this hope of a faster turnaround for me is the delays with patient numbers may have given time for the homework to already be done.  I wonder if the decision to proceed with a JV is only waiting for the BTD approval.  Merck.  Roche.  Whoever has been watching this procedure/compound evolve doesn't want to be 2nd guy through the door with a cheque book to be looking at the go getter signing a deal.  Simplistic visual but you get my point.  PDT is the new frontier and Theralase almost has a bow on this package, ready to serve.  I am hopeful this is the scenario.  
<< Previous
Bullboard Posts
Next >>